drugset / Trial / NCT00063388
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Determine tumor response rate and time to disease progression, survival and safety in total populations.
Timeline
- Start
- 2003-05
- Primary completion
- 2005-06
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |